Arnold Giammarco, the Army and National Guard veteran deported to Italy nearly five years ago, is back home in Connecticut with his wife and daughter. On May 14, 2011, federal immigration officials stormed Giammarco’s porch as he talked on the phone, ordered him to lie face down, handcuffed him and placed him in detention. The action was long after he had served time, many years earlier, for two 1997 larceny convictions and a 2004 drug conviction. He was detained without bond for 18 months, and sent to Italy on Nov. 26, 2012.
A Connecticut veterans’ leader Monday filed a federal class-action lawsuit on behalf of Army veterans nationwide who, like him, were given less than honorable discharges for behaviors later attributed to Post Traumatic Stress Disorder (PTSD). Stephen Kennedy of Fairfield, a lead plaintiff, is a decorated Army veteran and a founder of the state chapter of Iraq and Afghanistan Veterans of America. In the suit, he claims the Army isn’t following a Pentagon policy to make it easier for veterans with PTSD to upgrade their discharge statuses. The suit, filed in U.S. District Court in Bridgeport, is asking the court to order the Army to properly apply the policy. Issued by former Defense Secretary Chuck Hagel, the policy directs military review boards to give “liberal consideration” to veterans whose service-connected PTSD is diagnosed after discharge. A second plaintiff, Alicia J. Carson, a former Connecticut resident who was in the Army and the National Guard and now lives in Alaska, is also named in the lawsuit.
The Army is not properly monitoring the prescribing of medications to treat post-traumatic stress disorder (PTSD) in active-duty soldiers to ensure that antipsychotics and sedatives are not being used, a new government report says. The report by the Government Accountability Office (GAO) recommends that the Secretary of Defense direct the Army to monitor prescribing practices in order to detect medications that are discouraged under PTSD treatment guidelines. Those guidelines caution against the use of antipsychotics and benzodiazepines, a class of sedatives, because of their ineffectiveness and potential risk. “The Army does not monitor the prescribing of medications to treat PTSD on an ongoing basis,” says the report, led by the GAO’s director of health care, Debra Draper. “Without such monitoring, the Army may be unable to identify and address practices that are inconsistent with the guideline.”
The Department of Defense did not dispute the GAO recommendations, but argued that it has worked to reduce antipsychotic prescribing.